Related Experiment Videos
Sarcoidosis and the Heart
1Cardiology 111A, Veterans Affairs Health Care System, 3350 La Jolla Village Drive, La Jolla, CA 92161, USA. rshabetai@ucsd.edu
Insights
Sarcoid cardiomyopathy treatment addresses both systemic sarcoidosis and cardiac issues. Management varies based on patient symptoms, ranging from observation to pacemakers, defibrillators, or even heart transplantation.
Area of Science:
- Cardiology
- Immunology
- Systemic Diseases
Background:
- Sarcoid cardiomyopathy is a cardiac manifestation of systemic sarcoidosis.
- Clinical presentation and severity of cardiac involvement vary significantly among patients.
- Treatment requires a dual approach targeting both the systemic disorder and specific cardiac manifestations.
Purpose of the Study:
- To outline the diverse therapeutic strategies for sarcoid cardiomyopathy.
- To differentiate treatment based on the specific cardiac manifestations and patient's symptomatic status.
- To provide guidance on managing various cardiac complications associated with sarcoidosis.
Main Methods:
- Review of current therapeutic guidelines and clinical practices for sarcoid cardiomyopathy.
- Categorization of treatment approaches based on clinical presentation (asymptomatic, dilated cardiomyopathy, conduction abnormalities, arrhythmias, pericardial disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy).
- Discussion of pharmacologic, interventional, and surgical treatment options.
Main Results:
- Asymptomatic patients typically require no active treatment.
- Symptomatic patients receive tailored therapies including corticosteroids for systemic disease, and prednisone for cardiac involvement.
- Specific interventions include pacemakers for high-grade atrioventricular block, automatic implantable cardiac defibrillators (AICDs) for life-threatening arrhythmias, pericardial drainage or pericardiectomy for tamponade or constrictive pericarditis, calcium channel blockers for restrictive cardiomyopathy, and management of outflow obstruction in hypertrophic cardiomyopathy.
Conclusions:
- Treatment for sarcoid cardiomyopathy is highly individualized, depending on the specific cardiac manifestations.
- Corticosteroids are foundational for systemic sarcoidosis, while cardiac management is guided by the type and severity of heart involvement.
- Advanced therapies, including cardiac transplantation, may be necessary for end-stage disease.
Abstract:
The treatment of sarcoid cardiomyopathy can be considered in part the treatment of the systemic disorder, and in part cardiac involvement, the manifestations of which may differ greatly. Therapy for the systemic disease is corticosteroid. Therapy for cardiac involvement includes prednisone, but because treatment must ameliorate or abolish many differing manifestations, therapy differs among patients. Asymptomatic patients (the majority) who are free from serious manifestations of the disease do not require pharmacologic or interventional treatment. Patients with dilated cardiomyopathy require treatment for congestive heart failure. High-grade atrioventricular conduction delay usually necessitates a permanent electronic pacemaker. Life-threatening arrhythmia usually requires implantation of an automatic implantable cardiac defibrillator (AICD). Antiarrhythmic drugs may also be needed. Cardiac tamponade should be treated by drainage of pericardial fluid. Pericardiectomy is usually the appropriate treatment for patients who develop significant constrictive pericarditis. Calcium channel blockers may be helpful for severe diastolic dysfunction that occurs in those with restrictive cardiomyopathy. Therapy should be given to those few patients who manifest hypertrophic cardiomyopathy to relieve left ventricular outflow obstruction. Cardiac transplantation for intractable heart failure or arrhythmia may be needed.